Clinical trial
Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic…
NCT02500797 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT02500797 |
|---|---|
| Title | Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery |
| Official title | Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Locally Advanced Bone Sarcoma, Locally Advanced Dedifferentiated Liposarcoma, Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Soft Tissue Sarcoma, Metastatic Bone Sarcoma, Metastatic Liposarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Metastatic Unresectable Sarcoma, Pleomorphic Liposarcoma and 11 more |
| Intervention type | Biological, Other |
| Interventions | Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment |
| Enrollment | 164 |
| Start date | Aug 13, 2015 |
| Primary completion | Apr 1, 2019 |
| Completion | Apr 1, 2023 |
| First posted | Jul 17, 2015 |
| Last update posted | Oct 17, 2023 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: